COSCIENS Biopharma Inc T.AEZS

RE:"to the market"; "commercialization or licensing"

[prophetoffactz]

AEZS news release: "Cash from these products is planned to be used along with the Company’s revenue from the commercialization or licensing of its macimorelin product..."

I asked Perplexity Ai if approval for the pediatric market would enhance potential distribution efficiencies and allow AEZS to distribute the product by tself without a licensee. 

---

Yes, obtaining approval for the pediatric market would likely enhance efficiencies and enable Aeterna Zentaris to distribute its growth hormone deficiency diagnostic test (macimorelin) without licensing it out to another company.

Key Points

• Macimorelin is currently the only FDA and European Commission approved oral test for diagnosing adult growth hormone deficiency (AGHD).
• Aeterna Zentaris is developing macimorelin to also diagnose childhood-onset growth hormone deficiency (CGHD), which represents a significant unmet need.
• A recent clinical trial demonstrated the safety, tolerability and pharmacokinetics/pharmacodynamics of macimorelin in pediatric patients for diagnosing CGHD.
• If approved for the pediatric CGHD market in addition to the existing AGHD indication, Aeterna could market and distribute macimorelin themselves without needing to license it out.
• This would enhance efficiencies by allowing Aeterna to capture more revenue directly instead of sharing with a licensing partner.

So in summary, expanding macimorelin's approval to the pediatric CGHD market would enable Aeterna to commercialize it across both adult and pediatric indications, increasing their control over distribution and likely improving profit margins compared to an out-licensing arrangement.